Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells

Cancer Research

Volumn 66, Issue 20, 2006, Pages 10188-10198

  Riggs, Krista A ^a   Wickramasinghe, Nalinie S ^a   Cochrum, Renate K ^a   Watts, Mary Beth ^a   Klinge, Carolyn M ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; PROTEIN PS2; RECEPTOR PROTEIN; TAMOXIFEN; TESTOSTERONE DERIVATIVE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CHICKEN OVALBUMIN UPSTREAM PROMOTER II; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN INTERACTION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHICKENS; COUP TRANSCRIPTION FACTOR II; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 33750534786     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3937     Document Type: Article

References (49)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Clarke R, Liu MC, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003;22:7316-39.
3. Fisher B, Powles TJ, Pritchard KJ. Tamoxifen for the prevention of breast cancer. Eur J Cancer 2000;36:142-50.
4. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 2003;46:883-908.
5. Fasco MJ, Amin A, Pentecost BT, Yang Y, Gierthy JF. Phenotypic changes in MCF-7 cells during prolonged exposure to tamoxifen. Mol Cell Endocrinol 2003;206:33-47.
6. Pinto AE, Andre S, Laranjeira C, Soares J. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology 2005;37:45-50.
7. Benovic JL, Marchese A. A new key in breast cancer metastasis. Cancer Cell 2004;6:429-30.
8. Riggins RB, Thomas KS, Ta HQ, et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 2006;66:7007-15.
9. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. Estrogen receptor β (ERβ) level but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004;10:5769-76.
10. Chang HG, Kim SJ, Chung KW, et al. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor β but not the estrogen receptor α gene. J Mol Med 2004;5:5.
11. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004;10:7490-9.
12. Girault I, Lerebours F, Amarir S, et al. Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 2003;9:1259-66.
13. Keeton EK, Brown M. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-α and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 2005;19:1543-54.
14. Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 2004;24:5157-71.
15. Tsai SY, Tsai MJ. Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): coming of age. Endocr Rev 1997;18:229-40.
16. Pereira FA, Tsai MJ, Tsai SY. COUP-TF orphan nuclear receptors in development and differentiation. Cell Mol Life Sci 2000;57:1388-98.
17. Liu X, Huang X, Sigmund CD. Identification of a nuclear orphan receptor (Ear2) as a negative regulator of renin gene transcription. Circ Res 2003;92:1033-40.
18. Cooney AJ, Leng X, Tsai SY, O'Malley BW, Tsai MJ. Multiple mechanisms of chicken ovalbumin upstream promoter transcription factor-dependent repression of transactivation by the vitamin D, thryroid hormone, and retinoic acid receptors. J Biol Chem 1993;268:4152-60.
19. Lin F, Kolluri SK, Chen GQ, Zhang XK. Regulation of retinoic acid-induced inhibition of AP-1 activity by orphan receptor chicken ovalbumin upstream promoter-transcription factor. J Biol Chem 2002;277:21414-22.
20. 2/M progression of breast cancer by modulating the expression/activation of p21WaF1/CIP1, cyclin D1 and cdk2. Biochem Biophys Res Commun 2000;270:114-1153.
21. Sugiyama T, Wang JC, Scott DK, Grasnner DK. Transcriptional activation by the orphan nuclear receptor, chicken ovalbumin upstream promoter-transcription factor I. J Biol Chem 2000;275:3446-54.
22. Park J, Tsai, S. Tsai M. Molecular mechanism of chicken ovalbumin upstream promoter-transcription factor (COUP-TF) actions. Keio J Med 2003;52:174-81.
23. Shibata H, Nawaz Z, Tsai SY, O'Malley BW, Tsai MJ. Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT). Mol Endocrinol 1997;11:714-24.
24. Klinge CM. Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF). J Steroid Biochem Mol Biol 1999;71:1-19.
25. Liu Y, Yang N, Teng CT. COUP-TF acts as a competitive repressor for estrogen receptor-mediated activation of the mouse lactoferrin gene. Mol Cell Biol 1993;13:1836-46.
26. Lazennec G, Kern L, Valotaire Y, Salbert G. The nuclear orphan receptors COUP-TF and ARP-1 positively regulate the trout estrogen receptor gene through enhancing autoregulation. Mol Cell Biol 1997;17:5053-66.
27. Metivier R, Gay FA, Hubner MR, et al. Formation of an hERα-COUP-TFI complex enhances hERα AF-1 through Ser118 phosphorylation by MAPK. EMBO J 2002;21:3443-53.
28. Klinge CM SB, Driscoll MD, Sathya G, Bambara RA, Hilf R. Chicken ovalbumin upstream promoter-transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression. J Biol Chem 1997;272:31465-74.
29. Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998;95:2920-5.
30. More E, Fellner T, Doppelmayr H, et al. Activation of the MAP kinase pathway induces chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) expression in human breast cancer cell lines. J Endocrinol 2003;176:83-94.
31. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
32. Moreno-Cuevas JE, Sirbasku DA. Estrogen mitogenic action. III. Is phenol red a "red herring"? In Vitro Cell Dev Biol Anim 2000;36:447-64.
33. Lewis JS, Osipo C, Meeke K, Jordan VC. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 2005;94:131-41.
34. Brunner N, Frandsen TL, Holst-Hansen C, et al. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 1993;53:3229-32.
35. Lindberg MK, Moverare S, Skrtic S, et al. Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a "ying yang" relationship between ERα and ERβ in mice. Mol Endocrinol 2003;17:203-8.
36. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003;63:2434-9.
37. Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor β and variant isoforms in human breast cancer. Cancer Res 1999;59:5425-8.
38. Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 2005;67:335-76.
39. Navab R, Gonzalez-Santos JM, Johnston MR, et al. Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells. Cancer Res 2004;64:5097-105.
40. Moss EG, Taylor JM. Small-interfering RNAs in the radar of the interferon system. Nat Cell Biol 2003;5:771-2.
41. Coradini D, Pellizzaro C, Biffi A, et al. Effect of liposome-encapsulated α- or β-interferon on breast cancer cell lines. Anticancer Res 1998;18:177-82.
42. Klinge CM, Silver BF, Driscoll MD, Sathya G, Bambara RA, Hilf R. Chicken ovalbumin upstream promoter-transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression. J Biol Chem 1997;272:31465-74.
43. Wang Q, Bai Z, Li X, Hou L, Zhang B. The evidences of human orphan receptor COUP-TFII inhibiting telomerase activity through decreasing hTERT transcription. Cancer Lett 2004;214:81-90.
44. Park WC, Liu H, Macgregor Schafer J, Jordan VC. Deregulation of estrogen induced telomerase activity in Lamoxifen-resistant breast cancer cells. Int J Oncol 2005;27:1459-66.
45. Brunner N, Boysen B, Jirus S. et al. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen IC1 182,780 confers an early cross-resistance to the non-steroidal antiestrogen tamoxifen. Cancer Res 1997;57:3486-93.
46. Lee BC, Cha K, Avraham S, Avraham HK. Microarray analysis of differentially expressed genes associated with human ovarian cancer. Int J Oncol 2004;24:847-51.
47. Lin B, Chen GQ, Xiao D, et al. Orphan receptor CUUP-TF is required for induction of retinoic acid receptor β, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol Cell Biol 2000;20:957-70.
48. de Cremoux P, Tran-Perennou C, Brockdorff BL, et al. Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat Cancer 2003;10:409-18.
49. Bronzert DA, Greene GL, Lippman ME. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 1985;117:1409-17.